Active trials of ADCs in SCLC
| Agent | Phase | Status | Trial identifier | Indications | Sponsor |
|---|---|---|---|---|---|
| FZ-AD005 | I | Recruiting | NCT06424665 | Advanced solid tumors | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. |
| Sacituzumab govitecan | I/II | Recruiting | NCT04826341 | SCLC, extra-pulmonary small cell neuroendocrine cancer & homologous recombination-deficient cancers resistant to PARP inhibitors | National Cancer Institute |
| Sacituzumab govitecan | II | Active, not recruiting | NCT03964727 | Advanced solid tumors | Gilead Sciences |
| Sacituzumab govitecan | II | Not yet recruiting | NCT06667167 | ES-SCLC | Nir Peled |
| Sacituzumab tirumotecan | I/II | Recruiting | NCT04152499 | Advanced solid tumors | Klus Pharma Inc. |
| Datopotamab deruxtecan | I | Recruiting | NCT03401385 | Advanced solid tumors | Daiichi Sankyo |
| Ifinatamab deruxtecan | I/II | Recruiting | NCT04145622 | Advanced solid tumors | Daiichi Sankyo |
| Ifinatamab deruxtecan | Ib/II | Recruiting | NCT06362252 | ES-SCLC | Daiichi Sankyo |
| Ifinatamab deruxtecan | II | Active, not recruiting | NCT05280470 | ES-SCLC | Daiichi Sankyo |
| Ifinatamab deruxtecan | III | Recruiting | NCT06203210 | Relapsed SCLC | Daiichi Sankyo |
| HS-20093 | I | Recruiting | NCT05276609 | Advanced solid tumors | Hansoh BioMedical R&D Company |
| HS-20093 | III | Recruiting | NCT06498479 | Relapsed SCLC | Hansoh BioMedical R&D Company |
| HS-20093 | III | Not yet recruiting | NCT06526624 | Limited-stage SCLC | Hansoh BioMedical R&D Company |
| ABBV-706 | I | Recruiting | NCT05599984 | Advanced solid tumors | AbbVie |
| BL-B01D1 | Ia | Recruiting | NCT05194982 | Locally advanced or metastatic solid tumor | Sichuan Baili Pharmaceutical Co., Ltd. |
| BL-B01D1 | II | Recruiting | NCT05924841 | ES-SCLC | Sichuan Baili Pharmaceutical Co., Ltd. |
| BL-B01D1 | II | Recruiting | NCT06437509 | ES-SCLC | Sichuan Baili Pharmaceutical Co., Ltd. |
| BL-B01D1 | III | Recruiting | NCT06500026 | Relapsed SCLC | Sichuan Baili Pharmaceutical Co., Ltd. |
| BL-B01D1 | I/IIa | Recruiting | NCT06618287 | Advanced solid tumors | Bristol-Myers Squibb |
| Tusamitamab ravtansine | I | Active, not recruiting | NCT02187848 | Advanced solid tumors | Sanofi |
ADCs: antibody drug conjugates; SCLC: small cell lung cancer; ES-SCLC: extensive-stage SCLC